跳到正文

肿瘤领域的药物研发、临床数据、获批与治疗格局变化。

最新精选

第 981–1000 条 · 共 1,121 条
9月25日周五
  1. The Lancet60

    ROAM/EORTC-1308 III期试验:WHO 2级非典型脑膜瘤完全切除后放疗与观察对比

    ROAM/EORTC-1308 国际多中心、开放标签、III期随机对照试验比较了 WHO 2 级非典型脑膜瘤完全手术切除后辅助放疗与观察。研究结果提示,当患者更看重预防复发、而非放疗可能带来的迟发不良反应时,应考虑辅助放疗,这一做法可通过减少脑膜瘤复发使患者获益。具体决策应基于与患者的个体化讨论。

    推荐理由:原文给出非典型脑膜瘤术后放疗与观察的头对头III期结论,读者可据此理解复发预防与放疗迟发不良反应之间的权衡。

  2. FDA · 新闻稿62

    FDA受理拜耳Lynkuet(elinzanetant)新适应症sNDA并授予优先审评

    美国FDA已受理拜耳Lynkuet(elinzanetant)的补充新药上市申请(sNDA),并授予优先审评,拟用于治疗乳腺癌内分泌治疗相关的中重度血管舒缩症状。该消息由Business Wire发布。

    推荐理由:FDA受理拜耳elinzanetant新适应症补充申请并授予优先审评,读者可了解该药在乳腺癌内分泌治疗相关血管舒缩症状上的监管进展。

  3. MedCity News62

    礼来支付1亿美元与诺诚健华达成多靶点药物研发合作

    礼来将向北京诺诚健华支付1亿美元首付款及近期款项,启动一项多药物研发合作,针对最多5个未披露的靶点,诺诚健华将用其专有药物发现技术推进分子开发。若研发进展顺利,礼来还可能支付最高32.5亿美元的开发与商业里程碑款,诺诚健华另有资格获得获批产品销售的版税。诺诚健华专注肿瘤与自身免疫疾病药物,拥有ADC技术平台,目前在中国已有三款获批药物;礼来今年已宣布13项收购,并先后与信达生物、英矽智能达成合作。

    推荐理由:礼来年内多次与中国药企达成研发合作,这笔交易的首付款与里程碑结构可供观察跨国药企在华早期管线布局。

9月24日周四
  1. Matthew Herper67

    FDA 顾问委员会就 Grail 旗下 Galleri 多癌种血液筛查试验的三项投票问题给出结果:安全性问题 10 票赞成、0 票反对、0 票弃权;有效性问题 6 票赞成、4 票反对、0 票弃权;获益大于风险问题 7 票赞成、2 票反对、1 票弃权。

    引用Matthew Herper@matthewherper

    I'm live-tweeting the afternoon discussion of the FDA's advisory committee meeting on $GRAL's blood test to detect multiple types of cancer. This is a very interesting screening test. It definitely identifies cancers. But there are a good number of people who do not have cancer who will get a positive result, and a lot of patients who will get a negative result who do have cancer. One really big question is whether it's really right to say this test identifies cancer "early." And even tougher one is how to think about a test that might make patients skip existing screening tests -- that could mean, for instance, that more breast or colorectal cancers might be missed. The public hearing was very interesting. Some speakers, like Phil Castle from NCI, worried about the false negatives. There were also patients who felt they had been saved by the results of the test. I'll be threading my notes from the afternoon here. Forgive me for typos -- these things move fast.

    推荐理由:FDA 专家委员会对 Galleri 多癌种筛查试验的三项投票结果,呈现了有效性与获益风险上的分歧。

  2. HHS52

    美国卫生与公众服务部(HHS)在 X 上表示,FDA 提前数月批准了一款胰腺癌疗法,生存期较化疗翻倍。该帖引用 @FDA 的内容称,这是特朗普政府兑现加快审批、增加治愈手段承诺的体现,并附有《华盛顿观察家报》相关评论文章链接。HHS 正文称在总统领导下 FDA 正在变革癌症治疗,并引导读者查看 @FDA_KyleD 的更多内容。

    引用U.S. FDA@FDA

    The Trump administration is delivering on its promise: faster approvals, more cures, stronger American biotech. The FDA approved a treatment for pancreatic cancer months ahead of schedule — doubling survival vs. chemo. https://www.washingtonexaminer.com/op-eds/4733623/pancreatic-cancer-fda-approval-rasonque-daraxonrasib-trump/

  3. MHRA (英国药监)62

    MHRA 批准 lurbinectedin 联合阿替利珠单抗用于广泛期小细胞肺癌维持治疗

    MHRA 于 2026 年 9 月 23 日批准 lurbinectedin(Zepzelca)与阿替利珠单抗联用,用于一线阿替利珠单抗、卡铂和依托泊苷诱导治疗后未进展的广泛期小细胞肺癌成人患者的维持治疗。

    推荐理由:原文给出该药与阿替利珠单抗联用维持治疗的总生存期与无进展生存期数据,可据此判断其对广泛期小细胞肺癌二线维持治疗格局的影响。

9月23日周三
  1. Matthew Herper62

    Matthew Herper 在 X 上实时记录 FDA 顾问委员会对 Grail($GRAL)Galleri 多癌种血液检测的讨论。会上目前仅有公司方陈述,Grail 强调该检测能发现更多癌症并可定位,但未涉及对患者获益的更大问题;多位委员提出质疑,包括这种对医生的服务能否规模化,以及“有治愈意图但缺乏结局数据”。有委员追问为何 Grail 英国随机临床试验的对照组和主要终点未纳入简报文件,Grail 与 FDA 称这是双方协议所致;另有委员追问为何 Grail 另一项大型研究的许多患者未被纳入,Grail 称与数据提交时间有关。FDA 官员表示随访和结局数据超出本次所审评声称的范围。

    引用Matthew Herper@matthewherper

    I’m following the FDA advisory committee on $GRAL’s Galleri blood test for detecting multiple types of cancer today and will be posting my thoughts here. So far, we’ve seen only company presentations, usually the dullest part of an advisory panel. But there have been some interesting tidbits. First, Grail is leaning heavily into simply the idea that they detect more cancers and can localize them, not getting into larger questions about the benefit to patients from doing so. See this slide. Speaking as part of Grail’s presentation, Mylynda Massart, a family medicine at UPMC, argued that the test can fit will with existing cancer screening and is something that many patients are eager to use. The panelists, in their first questions, expressed skepticism. One asked if the incredible, white-glove treatment that Grail gives doctors now can really scale. Another responded a Grail comment: “You’re carefully choosing your words. It is curative intent but you do not have outcome data.” Another panelist asked why the control arm of Grail’s randomized clinical trial in the UK was not included in the briefing document; the primary outcome of that trial was not included, either. Grail and FDA said that based on the agreement they came to with the FDA. Another panelist asked why so many patients from Grail’s other big study were not included in the briefing material; Grail said that had to do with when the data were submitted. What’s interesting is that the FDA seems to be telling the panel to limit the scope of its discussion. An FDA official said that both follow-ups and outcome data were beyond the scope of the claim being considered.

    推荐理由:FDA 顾问委员会对 Galleri 多癌种血液检测的讨论,呈现审评中对结局数据与检测获益的分歧。

  2. Matthew Herper62

    记者 Matthew Herper 在 X 上实时记录 FDA 专家委员会对 Grail($GRAL)Galleri 多癌种血液检测的审议。目前仅公司方陈述,Grail 强调检测能发现更多癌症并定位,未深入讨论患者获益;UPMC 家庭医学医生 Mylynda Massart 称该检测可融入现有癌症筛查。

    推荐理由:记录 FDA 专家委员会对 Galleri 多癌种早筛检测的现场质疑,呈现审评焦点与证据缺口。

  3. NICE58

    NICE 发布最终指南,推荐 ibrutinib 联合 R-CHOP 作为未经治疗的套细胞淋巴瘤的治疗选择,可作为干细胞移植的替代方案,部分患者可能因此延长生存并延缓疾病进展。指南原文链接为 https://www.nice.org.uk/guidance/ta1193。

    推荐理由:NICE 最终指南将 ibrutinib 联合 R-CHOP 列为干细胞移植的替代方案,读者可据此了解套细胞淋巴瘤一线治疗的支付与推荐路径变化。